Amicus Therapeutics Inc FOLD

Amicus Therapeutics is an American healthcare company founded in 2002, with headquarters in Philadelphia, New Jersey. The company is a global biotech organisation engaged in the discovery, development, and delivery of therapies to treat a range of rare metabolic diseases.

Amicus is a highly patient-centric organisation, dedicated to supporting patients around the world who are living with many rare and often chronic diseases. The company has developed various life-changing therapies, such as Galafold, an oral precision medication for the treatment of Fabry disease. The company also develops AT-GAA, a novel treatment for Pompe disease and enzyme replacement therapies for Pompe diseases. Amicus runs patient advisory boards to enhance the understanding of the patient community and gain insight from those whose daily lives are affected by rare diseases. In addition, the company provides programs, services and activities aimed at enhancing the lives of those living with rare diseases.

Amicus Therapeutics’ stock is traded on the NASDAQ under the ticker FOLD. The company’s stock has been listed on the NASDAQ since June 2007. Amicus Therapeutics’ operates its business through several subsidiaries, including Celenex, Inc., Scioderm, MiaMed, Inc., Amicus Therapeutics International Holding LTD, Callidus Biopharma, Inc. and Amicus Therapeutics UK Limited.

Monitor FOLD share price changes by adding it to your eToro watchlist.